Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2016-05-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.
SHOX2 and PTGER4 will be analyzed via PCR.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging
NCT01653002
Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
NCT07257458
Analysis of Plasma Tumor DNA in Lung Cancer Patients
NCT01930474
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC
NCT02422628
The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer
NCT04018183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.
A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via PCR of blood plasma samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lung cancer
stage IA-IIIA lung cancer
lung cancer
PCR for SHOX2 and PTGER4
benign nodules
ruled out lung cancer via Operation or CT-scan follow-up
lung cancer
PCR for SHOX2 and PTGER4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lung cancer
PCR for SHOX2 and PTGER4
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Essen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kaid Darwiche
Priv.-Doz. Dr. med. Kaid Darwiche, head of department of interventional pneumology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kaid Darwiche, MD
Role: PRINCIPAL_INVESTIGATOR
head of deparment of interventional pneumology, Ruhrlandklinik, UHEssen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruhrlandklinik, Department of Interventional Pneumology
Essen, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weiss G, Schlegel A, Kottwitz D, Konig T, Tetzner R. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. J Thorac Oncol. 2017 Jan;12(1):77-84. doi: 10.1016/j.jtho.2016.08.123. Epub 2016 Aug 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHOX2 and PTGER4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.